Global Next Generation Cancer Diagnostics Market Projected to Reach $57.8 Billion by 2030
18 Aug 2023
Diagnostic Reagents
DUBLIN, Aug. 18, 2023 /PRNewswire/ -- The "Next Generation Cancer Diagnostics - Global Strategic Business Report" report has been added to
ResearchAndMarkets.com's offering.
The global Next Generation Cancer Diagnostics market, valued at US$6.7 billion in 2022, is anticipated to experience substantial expansion, reaching a projected size of US$57.8 billion by the year 2030.
This growth is expected to occur at an impressive Compound Annual Growth Rate (CAGR) of 31% over the analysis period from 2022 to 2030.
The report highlights key segments within the market, with qPCR & Multiplexing projected to achieve a CAGR of 33% and reach a market value of US$25.5 billion by the end of the analysis period. Moreover, considering the ongoing post-pandemic recovery, the growth trajectory of the Next Generation Sequencing segment has been adjusted to a revised CAGR of 26.1% for the next eight years.
Regional Analysis
The United States is a prominent player in the Next Generation Cancer Diagnostics market, estimated at a value of US$2 billion in 2022. In contrast, China, the world's second-largest economy, is forecasted to exhibit remarkable growth, projecting a market size of US$9.9 billion by the year 2030, driven by a robust CAGR of 30.1% over the analysis period from 2022 to 2030.
Other significant geographic markets include Japan and Canada, both predicted to witness growth rates of 27.9% and 26.3% respectively during the period from 2022 to 2030. Additionally, Germany, a key player within Europe, is expected to achieve a CAGR of approximately 21.5%.
The analysis encompasses a comprehensive evaluation of the global next-generation cancer diagnostics market, covering various geographic regions, technologies, and applications from 2014 to 2030.
The report provides insights into annual sales figures in US$ million, percentage CAGR, and market share for multiple technologies and applications, such as qPCR & Multiplexing, Next Generation Sequencing, LOAC & RT-PCR, Other Technologies, Biomarker Development, CTC Analysis, Proteomic Analysis, Genetic Analysis, Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening, Risk Analysis, and Other Applications.
Market Overview
Companies Mentioned include:
Abbott
Almac GroupAlmac Group
Genomic Health
Hologic
Koninklijke Philips N.V
Opko Health
Conclusion
With a projected CAGR of 31%, reaching a market value of US$57.8 billion by 2030, the global Next Generation Cancer Diagnostics market presents significant growth opportunities.
As the healthcare industry continues to evolve, the market is likely to witness continued innovation and advancements in diagnostic techniques, ultimately contributing to improved cancer detection and patient care.
For more information about this report visit https://www.researchandmarkets.com/r/k1y8wc
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.